Vascular Endothelial Growth Factor Receptor-1
"Vascular Endothelial Growth Factor Receptor-1" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A 180-kDa VEGF receptor found primarily in endothelial cells that is essential for vasculogenesis and vascular maintenance. It is also known as Flt-1 (fms-like tyrosine kinase receptor-1). A soluble, alternatively spliced isoform of the receptor may serve as a binding protein that regulates the availability of various ligands for VEGF receptor binding and signal transduction.
Descriptor ID |
D040281
|
MeSH Number(s) |
D08.811.913.696.620.682.725.400.950.100 D12.776.543.750.630.750.100 D12.776.543.750.750.400.910.100
|
Concept/Terms |
Vascular Endothelial Growth Factor Receptor-1- Vascular Endothelial Growth Factor Receptor-1
- Vascular Endothelial Growth Factor Receptor 1
- FLT1 Receptor Tyrosine Kinase
- VEGF Receptor flt-1 Protein
- VEGF Receptor flt 1 Protein
- VEGFR-1
- fms-Like Tyrosine Kinase
- Tyrosine Kinase, fms-Like
- Proto-Oncogene Protein flt
- Proto Oncogene Protein flt
- FLT1 RTK
- VEGF Receptor, FLT
- FLT VEGF Receptor
- Receptor, FLT VEGF
|
Below are MeSH descriptors whose meaning is more general than "Vascular Endothelial Growth Factor Receptor-1".
Below are MeSH descriptors whose meaning is more specific than "Vascular Endothelial Growth Factor Receptor-1".
This graph shows the total number of publications written about "Vascular Endothelial Growth Factor Receptor-1" by people in this website by year, and whether "Vascular Endothelial Growth Factor Receptor-1" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1998 | 0 | 1 | 1 |
2001 | 0 | 2 | 2 |
2002 | 0 | 1 | 1 |
2003 | 2 | 3 | 5 |
2004 | 2 | 1 | 3 |
2005 | 2 | 3 | 5 |
2006 | 4 | 5 | 9 |
2007 | 1 | 2 | 3 |
2008 | 0 | 2 | 2 |
2009 | 0 | 1 | 1 |
2010 | 2 | 4 | 6 |
2011 | 0 | 4 | 4 |
2012 | 0 | 4 | 4 |
2013 | 1 | 0 | 1 |
2014 | 0 | 3 | 3 |
2015 | 1 | 1 | 2 |
2016 | 1 | 0 | 1 |
2017 | 2 | 0 | 2 |
2018 | 2 | 2 | 4 |
2019 | 1 | 0 | 1 |
2020 | 1 | 1 | 2 |
2021 | 2 | 1 | 3 |
2022 | 0 | 5 | 5 |
2023 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Vascular Endothelial Growth Factor Receptor-1" by people in Profiles.
-
A dose escalation/expansion study evaluating dose, safety, and efficacy of the novel tyrosine kinase inhibitor surufatinib, which inhibits VEGFR 1, 2, & 3, FGFR 1, and CSF1R, in US patients with neuroendocrine tumors. Invest New Drugs. 2023 Jun; 41(3):421-430.
-
Aspirin Discontinuation at 24 to 28 Weeks' Gestation in Pregnancies at High Risk of Preterm Preeclampsia: A Randomized Clinical Trial. JAMA. 2023 02 21; 329(7):542-550.
-
Role of biomarkers (sFlt-1/PlGF) in cases of COVID-19 for distinguishing preeclampsia and guiding clinical management. Pregnancy Hypertens. 2023 Mar; 31:32-37.
-
Usefulness of angiogenic factors in prenatal counseling of late-onset fetal growth-restricted and small-for-gestational-age gestations: a prospective observational study. Arch Gynecol Obstet. 2023 11; 308(5):1485-1495.
-
Confirmation of preeclampsia-like syndrome induced by severe COVID-19: an observational study. Am J Obstet Gynecol MFM. 2023 01; 5(1):100760.
-
Angiogenic factors for planning fetal surveillance in fetal growth restriction and small-for-gestational-age fetuses: A prospective observational study. BJOG. 2022 10; 129(11):1870-1877.
-
Integrative clinical and molecular characterization of translocation renal cell carcinoma. Cell Rep. 2022 01 04; 38(1):110190.
-
Calcitonin Gene Related Peptide, Adrenomedullin, and Adrenomedullin 2 Function in Uterine Artery During Human Pregnancy. Endocrinology. 2022 01 01; 163(1).
-
Cost effectiveness of the sFlt1/PlGF ratio test as an adjunct to the current practice of evaluating suspected preeclampsia in the United States. Pregnancy Hypertens. 2021 Dec; 26:121-126.
-
FLT3 inhibitor based induction and allogeneic stem cell transplant in complete remission 1 improve outcomes in patients with newly diagnosed Acute Myeloid Leukemia with very low FLT3 allelic burden. Am J Hematol. 2021 08 01; 96(8):E275-E279.